The main event in blood coagulation is the thrombincatalyzed conversion of fibrinogen into fibrin. This singular transformation of a soluble protein into an insoluble polymeric network occurs with faultless precision. Abnormalities of fibrin polymerization can lead to hemorragic and thrombotic disorders. Increased fibrinogen plasma concentration (Fg) and fibrin polymerization rate (FPR) could be additional risk factors associated with atherothrombosis in antiphospholipid syndrome (APS) and in systemic lupus erythematosus (SLE). Our objective was to investigate Fg and FPR in consecutive patients with APS and SLE. Thirty-nine patients and 31 ageand gender-matched healthy controls were studied. Sixteen patients had primary APS, 13 patients had SLE, and 10 patients had SLE plus APS. The mean of the FPR was significantly increased (0.2799 ± 0.091) in patients with APS plus SLE as compared with the control group (0.2052 ± 0.055) (p<0.05). Fg was higher in APS plus SLE (3.15 g/L ± 0.43) and in primary APS (3.03 g/L ± 0.29) than in controls (2.87 g/L ± 0.49). Our results demonstrated an increased FPR in patients with APS plus SLE. This phenomenon could be an additional risk factor for thrombosis in these autoimmune diseases.
1. Angles-Cano E, Guillin MC. Antiphospholipid antibodies and the coagulation cascade. Rheum Dis Clin North Am2001;27:573-573.
2.
2. Shoenfeld Y. The anti-phospholipid (Hughes) syndrome: A crossroads of autoimmunity and atherosclerosis. Lupus1997;6:559-559.
3.
3. George J, Shoenfeld Y, Harats D. The involvement of B2-Glycoprotein 1 (B2GP1) in human and murine atherosclerosis. J Autoimmunity1999;13:57-57.
4.
4. Urowitz MB, Bookman AM, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of SLE. Am J Med1976;60:221-221.
5.
5. Asherson R, Cervera R. The antiphospholipid syndrome: A syndrome in evolution. Ann Rheum Dis1992;51:147-147.
6.
6. Doherty NE, Siegel RJ. Cardiovascular manifestations of systemic lupus erythematosus. Am Heart J1985; 110:1257-1257.
7.
7. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis1986;6:131-131.
8.
8. Kullo IJ, Gau GT, Tajik AJ. Novel risk factors for atherosclerosis. Mayo Clin Proc2000;75:369-369.
9.
9. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum1999;42: 1309-1309.
10.
10. Tan EN, Cohen AS, Fries JF, et al. The 1982 revised criteria fro the classification of systemic erythematosus lupus. Arthritis Rheum1982;25:1271-1271.
11.
11. Clauss A. Measurement of fibrinogen. Acta Haematol1957;17:237-237.
12.
12. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med1993;118:956-956.
13.
13. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham study. JAMA1987;258:1183-1183.
14.
14. Wilhelmsen L, Svardsudd K, Korsan-Benggsten K, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med1984;311:501-501.
15.
15. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park heart study. Lancet1986;2:533-533.
16.
16. Ma J, Hennekens CH, Ridker PM, Stampfer MJ. A prospective study of fibrinogen and risk of myocardial infarction in the physicians health study. J Am Coll Cardiol1999;33:134-134.
17.
17. Amrani DL. Regulation of fibrinogen biosynthesis: Glucocorticoid and interleukin-6 control. Blood Coag Fibrinolysis1990:1:443-443.
18.
18. Ames PRJ, Alves J, Pap AF, Ramos P, Khamashta MA, Hughes GRV. Fibrinogen in systemic lupus erythematosus: More than an acute phase reactant?J Rheumatol2000;27: 1190-1190.
19.
19. Lee AJ, Lowe GDO, Smith WCS, Tunstall-Pedoe H. Plasma fibrinogen in women: Relationship with oral contraception, the menopause and hormone replacement therapy. Br J Haematol1993;83:616-616.
20.
20. Balleisen L, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII, and fibrinogen in an industrial population. I. Baseline data on the relation to age, gender, body weight, smoking, alcohol, pill using and menopause. Thromb Haemost1985;54:475-475.
21.
21. Ernst E, Matrai A, Schmolzl C, Magyarosy I. Dose-effect relationship between smoking and blood rheology. Br J Haematol1987;65:485-485.
22.
22. Folsom A. Fibrinogen and cardiovascular risk in the Atherosclerosis and Risk in Communities (ARIC) study. In: Ernst E, ed. Fibrinogen, A New Cardiovascular Risk Factor. Oxford, England: Blackwell, 1992:128-128.
23.
23. Smith EB, Thomson WD. Fibrin as a factor in atherogenesis. Thromb Res1994;73:1-1.
24.
24. Sironi M, Braviario F, Proserpio P, et al. IL-1 stimulates IL-6 production in endothelial cells. J Immunol1989; 142:549-549.
25.
25. Hardin JA, Cronlund M, Haber H, Bloch KJ. Activation of clotting in SLE. Relationship to disease activity. Am J Med1978;65:430-430.
26.
26. Inoh M, Tokuda M, Kiuchi H, Kurata N, Takahara J. Evaluating SLE disease activity using molecular markers of hemostasis. Arthritis Rheum1996;39:287-287.
27.
27. Jurado M, Paramo JA, Gutierrez-Pimentel M, Rocha E. Fibrinolytic potential and antiphospholipid antibodies in SLE and other connective tissue disorders. Thromb Haemost1992;68:516-516.
28.
28. Salazar-Paramo M, Garcia de la Torre I, Fritzler MJ, Loyau S, Angles-Cano E. Antibodies to fibrin-bound tissue-type plasminogen activator in SLE are associated with Raynaud's phenomenon and thrombosis. Lupus1996; 5:275-275.
29.
29. Awada H, Barlowatz-Meimon G, Dougados M, Maisonneuve P, Sultan I, Amor B. Fibrinolysis abnormalities in SLE and their relation to vasculitis. J Lab Clin Med1988;111:229-229.
30.
30. Hazelton RA, Lowe GDO, Forbes CD, Sturrock RD, Increased blood and plasma viscosity in SLE. J Rheumatol1985;12:616-616.
31.
31. Ernst E, Hein A, Meurer M, Ruzicka T. Blood rheology in lupus eryhtematosus. Ann Rheum Dis1991;50:710-710.
